FDA Inspection
Boehringer Ingelheim Pharma Gmbh & Co KgBoehringer Ingelheim Pharma Gmbh & Co Kg – FDA Inspection, Jul 10, 2018
Record Details
This FDA Inspection record concerns Boehringer Ingelheim Pharma Gmbh & Co Kg, with an inspection on July 10, 2018, issued by the Office of Inspections and Investigations, covering human drugs.
- People
- Michael Shanks (Issuing Officer)
- Zhong Li
View Company Profile
ID · 5f713047-3ac2-41a9-934a-7d5a75cb09f9
Inspection Facts
- Inspection number
- 1060777
- FDA center
- Human Drugs
- Outcome
- Form 483 issued
Other FDA inspections of Boehringer Ingelheim Pharma Gmbh & Co Kg
13| Date | Classification | Office | Project area |
|---|---|---|---|
| July 22, 2022 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| September 19, 2019 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| August 15, 2019 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
| April 5, 2019 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| October 19, 2018 | Not classified | Office of Inspections and Investigations |
Other documents for Boehringer Ingelheim Pharma Gmbh & Co Kg
- FDA Inspection 1208927 - 2022-07-22
- FDA Inspection 1102691 - 2019-09-19
- FDA Inspection 1107587 - 2019-08-15
- FDA Inspection 1086418 - 2019-04-05
- FDA Inspection 1072835 - 2018-10-19
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.